Celebrating 25 Years of Cellex: A Symposium for Cell and Gene Therapy Experts
On November 8, 2026, the Cellex Symposium 2026 was held at the Wasserturm Hotel in Cologne, marking a significant milestone as Cellex Cell Professionals celebrated its 25th anniversary. This year, the event highlighted the theme, “Cell and Gene Therapy at a Turning Point,” and brought together over 100 researchers, clinicians, and industry experts. The symposium featured ten scientific presentations distributed across three sessions, meticulously covering the entire spectrum from research and development to global commercialization.
The inaugural session, titled "Translating Cells to Clinical Impact," set the stage for dynamic discussions on the application of cell therapies in clinical settings. Experts such as Dr. Hyatt Balke-Want from Cologne University Hospital, Jens Altrichter from Artcline GmbH, and Matthias Domogalla from Cellex explored critical topics including genetically modified T cells and the use of allogeneic immune cell therapies for treating sepsis. They emphasized the importance of adhering to Good Manufacturing Practices (GMP), articulated as a key determinant for production performance.
The second session was dedicated to addressing therapeutic approaches for challenging cancers and genetic disorders. Presenters, including Professor Elke Jäger from North-West Hospital in Frankfurt and Frank Buchholz from Technical University of Dresden, introduced groundbreaking methodologies such as peptide vaccines, genetic editing platforms, and T cells expressing T-cell receptors (TCRs) aimed at targeting the PRAME antigen. Additionally, they discussed challenges regarding hard-to-target antigens in solid tumors and hematological malignancies.
Throughout the event, expert panels engaged in moderated discussions on various contemporary topics, including the role of artificial intelligence in regulated environments and the feasibility of maintaining product quality across multiple manufacturing sites. The closing session, aptly named "Market Realities," delved into the complexities of scaling, addressing topics such as GMP adherence for raw materials, integrated CDMO models, and China's emerging role in the global biotechnology landscape. Key figures like Rachel Atlee from Akron Bio, Dr. Suvi Annala from Cellex, and Ping Shek from STBio Limited offered insights during this session.
Professor Martin Wermke, Director of the Early Clinical Trials Unit at the National Center for Tumor Diseases in Dresden, stated, "This event was an exceptional opportunity to reconnect with friends and colleagues in the field of cell and gene therapy. In just one day, the symposium covered the entire journey from research and development to commercialization. The open exchange between academia and industry highlighted the fact that today's decisions in our field will shape the next decade."
Dr. Armin Ehninger, Cellex’s Chief Scientific and Strategic Officer, reiterated the importance of collaboration, noting, "Advanced therapies will only reach patients at scale if science, manufacturing, and regulatory expertise advance hand-in-hand. This symposium encompassed all these perspectives in one space, and we look forward to continuing these discussions with our partners."
Over the past 25 years, Cellex has evolved from a service provider for apheresis to a prominent Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy. With more than a decade of experience in producing both autologous and allogeneic products, Cellex supports pharmaceutical, biotechnology, and academic partners throughout preclinical and clinical development stages, as well as in commercial manufacturing. The company combines its GMP manufacturing expertise with capabilities in sourcing starting cellular materials and supply chain management. For more information, visit
Cellex.
Contact Information
Elena Görris
Strategic Marketing Director
Cellex Cell Professionals GmbH
Email: [email protected]
Tel: +49 151 12410817